January 2020 in “Archives of urology” Finasteride, a drug used for certain conditions, can cause serious side effects like sexual dysfunction, suicidal thoughts, and increased diabetes risk, and there's a need for more awareness and research about these effects.
1 citations
,
January 2014 The F9 formulation of Finasteride tablets, using Eudragit, successfully controlled drug release.
September 2022 in “XXXIX Congresso Brasileiro de Reumatologia” Tofacitinib may effectively treat skin symptoms in difficult cases of dermatomyositis.
December 2013 in “The Journal of Urology” March 2023 in “The Journal of Urology” Nocturia cases increased, but medication use declined, suggesting under-treatment.
7 citations
,
September 2024 in “The Journal of Dermatology” Ritlecitinib helps regrow hair in people with alopecia totalis and universalis and is safe to use.
October 2021 in “European urology open science” 9 citations
,
September 1996 in “PubMed”
71 citations
,
November 2012 in “Expert Opinion on Drug Safety” 5-alpha reductase inhibitors can cause sexual side effects like erectile dysfunction and reduced sexual desire, sometimes lasting after stopping the drug.
April 2015 in “Reactions Weekly” Finasteride toxicity information is limited, poor quality, and biased.
September 2023 in “Journal of the American Academy of Dermatology” GoodRx.com helps find the cheapest options for finasteride, a medication not often covered by insurance.
January 2025 in “International Journal of Dermatology Venereology and Leprosy Sciences” Tofacitinib improved hair regrowth and quality of life in children with alopecia areata, with mild side effects.
January 2007 in “Pharmaceutical Journal of Chinese People's Liberation Army” The two finasteride tablets are bioequivalent.
57 citations
,
July 2016 in “The Journal of Sexual Medicine” 5α-reductase inhibitors increase the risk of sexual dysfunction, especially in men with enlarged prostate.
12 citations
,
February 2003 in “European Urology Supplements” Dutasteride reduces DHT more effectively than finasteride.
Finasteride is a safe and effective long-term treatment for male hair loss, especially when started early.
1 citations
,
July 2019 in “Medicina Clínica (English Edition)” Tofacitinib partially improved hair regrowth in a patient with severe hair loss.
70 citations
,
April 2016 in “Experimental Dermatology” A patient with alopecia areata regrew hair after taking tofacitinib and showed changes in certain blood and skin markers.
23 citations
,
January 2007 in “Archives of Andrology” Finasteride may negatively affect male fertility.
39 citations
,
May 2011 in “Movement Disorders” Finasteride may help reduce symptoms in male Tourette syndrome patients.
9 citations
,
January 2017 in “Farmacia” Finasteride can still be used for hair loss with careful consideration of side effects and patient information.
31 citations
,
September 2008 in “International Journal of Andrology” 5-alpha-reductase inhibitors may cause a low incidence of erectile dysfunction that decreases over time.
2 citations
,
February 2007 in “PubMed” Dutasteride is cheaper than finasteride for treating benign prostatic hyperplasia.
11 citations
,
January 2006 in “Analytica Chimica Acta” Validated method reliably measures finasteride in tablets using liquid chromatography.
Oral tofacitinib effectively treats alopecia areata long-term with manageable side effects.
2 citations
,
May 2019 in “PubMed” Oral finasteride and dutasteride may negatively affect erectile function in rats.
4 citations
,
January 2002 Alpha-blockers and Finasteride effectively manage BPH symptoms long-term.
10 citations
,
October 2010 in “International Journal of Andrology” Finasteride doesn't affect oral testosterone undecanoate, and high DHT levels may cause acne, prostate issues, and hair loss.
November 2023 in “Indian Dermatology Online Journal” Tofacitinib was effective for severe, treatment-resistant hair loss without side effects.
18 citations
,
November 2012 in “Current opinion in urology” Finasteride and dutasteride are equally effective and safe for treating benign prostatic hyperplasia.